4.8 Article

Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers

Journal

CANCER RESEARCH
Volume 74, Issue 4, Pages 1141-1152

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-2247

Keywords

-

Categories

Funding

  1. National Cancer Institute [NIH P50-CA105009, NIH U01 CA-152990, NIH R21 CA-156021]
  2. Honorable Tina Brozman 'Tina's Wish' Foundation
  3. Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  4. Robert and Debra First Fund
  5. Gamel Family Fund
  6. Canadian Institutes of Health Research Fellowship
  7. Kaleidoscope of Hope Foundation Young Investigator Research Grant
  8. National Health and Medical Research Council [APP 1042358]

Ask authors/readers for more resources

The fallopian tube is now generally considered the dominant site of origin for high-grade serous ovarian carcinoma. However, the molecular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few experimental studies examining the transformation of human fallopian tube cells. Prompted by recent genomic analyses that identified cyclin E1 (CCNE1) gene amplification as a candidate oncogenic driver in high-grade serous ovarian carcinoma, we evaluated the functional role of cyclin E1 in serous carcinogenesis. Cyclin E1 was expressed in early- and late-stage human tumor samples. In primary human fallopian tube secretory epithelial cells, cyclin E1 expression imparted malignant characteristics to untransformed cells if p53 was compromised, promoting an accumulation of DNA damage and altered transcription of DNA damage response genes related to DNA replication stress. Together, our findings corroborate the hypothesis that cyclin E1 dysregulation acts to drive malignant transformation in fallopian tube secretory cells that are the site of origin of high-grade serous ovarian carcinomas. (C)2013 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available